Corona virus- British press reports success with Japanese drug in China.

[Graham49]

Japanese flu drug 'clearly effective' in treating coronavirus, says China

Shares in Fujifilm Toyama Chemical, which developed favipiravir, surged after praise by Chinese official following clinical trials

Coronavirus – latest updates

See all our coronavirus coverage

Justin McCurry in Tokyo

Wed 18 Mar 2020 11.56 GMT First published on Wed 18 Mar 2020 06.55 GMT

Shares

58173

[cesces]

In trial drugs are not so useful or accessible.

Repurposed ones are more so.

[Graham49 in reply to cesces]

From Wikaedia

In 2014, Japan approved Favipiravir for treating viral strains unresponsive to current antivirals.[18] Toyama Chemical initially hoped that Avigan would become a new influenza drug that could replace Tamiflu. However, animal experiments show the potential for teratogenic effects on fetuses, and the approval of production by The Ministry of Health, Labor and Welfare was greatly delayed and the production condition is limited only in an emergency in Japan.[19]

In March 2015, the US Food and Drug Administration completed a Phase III clinical trial studying the safety and efficacy of Favipiravir in the treatment of influenza.[20]

[cesces in reply to Graham49]

Did it pass phase 3?

[Graham49 in reply to cesces]

No results posted for some reason.

ClinicalTrials.gov

Find StudiesFind Studies Menu

About StudiesAbout Studies Menu

Submit StudiesSubmit Studies Menu

ResourcesResources Menu

About SiteAbout Site Menu

HomeSearch ResultsStudy Record Detail Save this study

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02026349

Recruitment Status : Completed

First Posted : January 3, 2014

Last Update Posted : November 11, 2015

Sponsor:

MDVI, LLC

Collaborator:

MediVector, Inc.

Information provided by (Responsible Party):

MDVI, LLC

Study DetailsTabular View No Results PostedDisclaimerHow to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :Completed

Actual Primary Completion Date :March 2015

Actual Study Completion Date :March 2015

Certification/Extension First Submitted :

[cesces in reply to Graham49]

Hmmm that's sort of important.

[cesces in reply to Graham49]

What is not safe enough for flu, may be plenty safe for covid.

And to make it to phase, it already had to prove a certain level of safety.

Maybe they just need to start a covid phase 3.

[j-o-h-n]

Hey any country that can defeat Godzilla has my vote..........

Good Luck, Good Health and Good Humor.

j-o-h-n Friday 03/20/2020 6:51 PM DST